WAMD
Clinical trials for WAMD explained in plain language.
Never miss a new study
Get alerted when new WAMD trials appear
Sign up with your email to follow new studies for WAMD, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Potential game changer: eye implant could drastically reduce injections for blinding disease
Disease control OngoingThis study is testing if a new, long-acting eye implant (EYP-1901) can work as well as standard aflibercept injections for treating wet age-related macular degeneration (AMD), a leading cause of vision loss. It aims to see if the implant can maintain or improve vision while reduc…
Matched conditions: WAMD
Phase: PHASE3 • Sponsor: EyePoint Pharmaceuticals, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
Eye implant aims to free patients from frequent injections for blinding disease
Disease control OngoingThis study is testing whether a new, long-acting eye implant (EYP-1901) can work as well as the current standard treatment (aflibercept injections) for wet age-related macular degeneration (AMD). It will involve about 400 people who have this eye condition. The main goal is to se…
Matched conditions: WAMD
Phase: PHASE3 • Sponsor: EyePoint Pharmaceuticals, Inc. • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC